Developer docs
API playgroundTry for free, no card

Search company profiles

RegMed XB

Full company profile

uuid002ue3b

Namestring
RegMed XB
Legal namestring
Stichting REGenerative MEDicine crossing Borders
Websiteurl
regmedxb.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

RegMed XB is a Dutch-Flemish public-private research consortium (operating as Stichting REGenerative MEDicine crossing Borders in the Netherlands and RegMed XB Flanders vzw in Belgium) that accelerates the translation of regenerative medicine from academic research into clinical application. The organization runs five focused Moonshot research programs targeting Cardiovascular regeneration, Type 1 Diabetes cure, Eye (corneal) restoration, Kidney disease (including bioengineered subunits and a wearable artificial kidney now in first-in-human trials), and Osteoarthritis (bio-artificial joints), spanning cell therapy, gene therapy, tissue engineering, organoid technology, biofabrication/3D bioprinting, and biomaterial implants within the ATMP category.

The consortium is anchored by the RegMed XB Pilot Factory, described as one of the largest international regenerative medicine infrastructures, which provides scale-up and de-risking capacity for portfolio projects. It is supported by an ecosystem of more than 60 partners across health foundations (Dutch Heart Foundation, Kidney Foundation, Diabetes Fonds, Oogfonds, ReumaNederland, Dutch Brain Foundation), 11+ academic institutions (LUMC, UMC Utrecht, KU Leuven, TU/e, Maastricht University/MERLN), 30+ industrial partners (including Mimetas for organ-on-chip), and 7 government bodies (Health Holland, RVO, National Growth Fund, and the Ministries of EZK, OCW, and VWS).

RegMed XB does not sell commercial products; instead its revenue mechanics comprise government grants and public funding, seed capital deployment through the FIRST fund (co-managed with Biogeneration Ventures), Valorization Vouchers and business development services, and partner contributions. The value proposition for its stakeholders is the de-risking of promising concepts from academia through proof-of-concept and early clinical stages before commercial partners take them forward, with the organization monetizing principally through program execution, technology transfer, and convening rather than direct product sales.

Short descriptiontext

RegMed XB is a Dutch-Flemish public-private consortium that accelerates regenerative medicine from research to clinic via five Moonshot programs (Cardiovascular, Diabetes, Eye, Kidney, Osteoarthritis), the Pilot Factory infrastructure, and a 60+ partner ecosystem across academia, health foundations, industry, and government.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersUtrecht, Netherlands
HQ citystring
Utrecht
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative medicine research, tissue engineering infrastructure, cell therapy development, ATMP manufacturing services, biofabrication and bioprinting
Industry2 codes
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAGAGAD
Cell Banking & Viral Seed Services (MCB/WCB/VSB)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Medicine Research and ATMP Infrastructure
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Government Grants and Public Funding
TypeManaged Services
Description

RegMed XB receives support from national and local governments including Health Holland, Ministry of EZK, Ministry of OCW, Ministry of VWS, Netherlands Enterprise Agency (RVO), and National Growth Fund (NGF) to de-risk promising concepts from academia to proof of concept or initial clinical trial stages before commercial partners take over.

regmedxb.com
2Seed Capital and Investment Fund Management
TypeLicensing Royalties
Description

Manages seed capital programs including the FIRST fund (jointly with BGV) for early-stage investment in regenerative and cardiovascular medicine. Receives funding from Thematic Tech Transfer (TTT) program and SRGO subsidy scheme.

regmedxb.com
3Valorization Services
TypeProfessional Services
Description

Provides Valorization Vouchers and business development support to help innovators accelerate, de-risk, and scale regenerative therapies. Revenue generated through service fees and successful technology transfer/valorization of research outcomes.

regmedxb.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

RegMed XB runs multi-year regenerative medicine research programs (five Moonshots covering cardiovascular, Type 1 diabetes, eye, kidney, and osteoarthritis indications) and provides shared Pilot Factory infrastructure that researchers and companies use to scale and de-risk Advanced Therapy Medicinal Products (ATMPs). It supplements these with valorization services (business development, Valorization Vouchers) and the FIRST seed capital fund co-managed with Biogeneration Ventures, functioning as a public-private translation platform rather than a product vendor.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Growing 100 nephrons per organoid with scalability to 50,000 nephrons in large organoid sheets (Kidney Moonshot)
+4 more records
Product overview1 text field

RegMed XB is a Dutch-Flemish research consortium (Stichting REGenerative MEDicine crossing Borders and RegMed XB Flanders vzw) operating as a platform organization that accelerates regenerative medicine through five interconnected offerings: (1) Five Moonshot research excellence programs (Cardiovascular, Diabetes, Eye, Kidney, Osteoarthritis) targeting specific chronic diseases through advanced therapy medicinal products; (2) The Pilot Factory, a large-scale infrastructure facility enabling researchers and companies to scale and de-risk regenerative therapies toward market; (3) Valorization services including Valorization Vouchers and business development support; (4) Seed capital through the FIRST fund for early-stage companies; and (5) An annual conference serving as a community platform for the regenerative medicine ecosystem. The organization functions as a public-private partnership connecting academic institutions, health foundations, industrial partners, and governmental agencies.

Product and service3 records
1Pilot Factory (regenerative medicine infrastructure)
CategoryRegenerative medicine infrastructure services
2Valorization Team Services
CategoryBusiness development and valorization services
3Seed Capital & FIRST Fund
CategorySeed capital and early-stage investment
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership18 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-02
Description

On July 2, 2025, RegMed XB and Inserm (French National Institute of Health and Medical Research) signed a Memorandum of Understanding to strengthen scientific collaboration in biomedical research. The signing was hosted by the French Ambassador to the Netherlands at the French Residence in The Hague.

2Nakanoshima Qross
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-14
Description

RegMed XB and Nakanoshima Qross (International Hub for Future Medicine based in Osaka, Japan) signed a memorandum of understanding to promote cooperation in regenerative medicine. Nakanoshima Qross delegation visited in October 2025 to strengthen ties.

regmedxb.com
3Dutch Heart Foundation (Hartstichting)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Health foundation involved in defining research objectives and providing guidance in research to ensure focus on patients. Co-governs the Cardiovascular Moonshot.

regmedxb.com
4Dutch Kidney Foundation (Nierstichting)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Health foundation driving the Kidney Moonshot, defining research objectives and co-governing the program. Supports first-in-human clinical trials for wearable artificial kidney.

regmedxb.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Health foundation focused on Type 1 diabetes research, co-governing the Diabetes Moonshot and supporting Cure One research center at LUMC.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Foundation with goal to cure Type 1 diabetes, investing nationally and internationally in fundamental and clinical research for a cure.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Health foundation focused on preventing eye diseases and supporting people with visual impairments, co-governing the Eye Moonshot.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Health foundation for rheumatism patients (2+ million people), co-governing the Osteoarthritis Moonshot focused on bio-artificial joint development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dutch Brain Foundation supporting brain-related research within the RegMed XB ecosystem.

Strategic tierCoreTypeOthers
Description

Governmental partner providing funding and support for Life Sciences & Health innovation in the Netherlands.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership for cardiovascular research collaboration, joint valorization activities, and community events.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

€3.5 million Interreg-cofunded initiative led by Biovia to reinforce cross-border ecosystem for ATMPs in Flanders and South Netherlands. RegMed XB is a proud contributor.

Strategic tierMajorTypeTechnology or Integration
Description

Industrial partner specializing in organ-on-a-chip technology, collaborating with Kidney Moonshot for kidney research and development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Top-rated academic institution contributing researchers and expertise to multiple Moonshots. Home to Prometheus platform for Skeletal Tissue Engineering.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leiden University Medical Center leading Diabetes Moonshot and hosting Cure One research center for Type 1 diabetes cure research.

16UMC Utrecht
Strategic tierCoreTypeStrategic or Co-development Partner
Description

University Medical Center leading Kidney Moonshot (with Prof. Marianne Verhaar) and Cardiovascular Moonshot research activities.

regmedxb.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partner contributing expertise in biomedical engineering, biomaterials, and biofabrication for Osteoarthritis and Kidney Moonshots.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partner hosting MERLN Institute for Technology-Inspired Regenerative Medicine, contributing to multiple Moonshots including Diabetes and Osteoarthritis.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Aspect Biosystems
TypeEmerging player
Description

Canadian biotech developing 3D bioprinted tissue therapeutics with focus on metabolic disease and ophthalmology. Directly comparable on biofabrication and tissue engineering technology overlap with RegMed XB's Osteoarthritis and Eye Moonshots.

TypeBroad incumbent
Description

Swiss-headquartered global contract development and manufacturing organization (CDMO) with the largest cell and gene therapy manufacturing footprint. Relevant as the leading ATMP manufacturing partner/infrastructure provider that RegMed XB's Pilot Factory competes with or routes work to.

TypeBroad incumbent
Description

US-headquartered commercial regenerative medicine company marketing wound care and surgical biologics products. Comparable as a commercial-stage player in regenerative medicine with overlapping musculoskeletal and tissue engineering focus.

TypeDirect peer
Description

California state-funded agency created by voter proposition that funds stem cell and regenerative medicine research across academic and commercial entities. Operates a comparable model of public funding flowing through a coordinating consortium to advance regenerative therapies.

TypeEmerging player
Description

Australia-headquartered clinical-stage cell therapy company developing mesenchymal lineage cell therapies for inflammatory and cardiovascular diseases. Overlaps with RegMed XB's Cardiovascular Moonshot in regenerative approaches to heart failure.

TypeEmerging player
Description

US commercial-stage cell therapy company marketing MACI (autologous chondrocyte implant for cartilage repair) and Epicel. Directly comparable on cartilage regeneration with overlap to RegMed XB's Osteoarthritis Moonshot.

TypeDirect peer
Description

International stem cell research consortium with nodes in Denmark, the Netherlands, and Australia, funded by the Novo Nordisk Foundation. Directly comparable as a multi-institutional regenerative medicine research consortium with significant long-term foundation backing.

TypeDirect peer
Description

Canadian regenerative medicine consortium that operates a similar public-private model with academic-industry partnerships, pilot manufacturing facilities, and venture creation to commercialize cell and gene therapies. Directly comparable in structure and mission to RegMed XB.

TypeDirect peer
Description

UK-based non-profit consortium accelerating cell and gene therapy commercialization through shared infrastructure, skills development, and clinical trial support. Closely analogous to RegMed XB's consortium-driven ATMP acceleration model across the UK ecosystem.

TypeRegional player
Description

Belgium-headquartered stem cell technology company developing iPSC-derived cardiac and neural cell models and manufacturing services. Comparable as a Benelux-based stem cell specialist serving drug discovery and regenerative medicine applications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights1 record

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RegMed XB

Regenerative Medicine Research and ATMP Infrastructureregmedxb.com

RegMed XB is a Dutch-Flemish public-private consortium that accelerates regenerative medicine from research to clinic via five Moonshot programs (Cardiovascular, Diabetes, Eye, Kidney, Osteoarthritis), the Pilot Factory infrastructure, and a 60+ partner ecosystem across academia, health foundations, industry, and government.

What RegMed XB does

RegMed XB is a Dutch-Flemish public-private research consortium (operating as Stichting REGenerative MEDicine crossing Borders in the Netherlands and RegMed XB Flanders vzw in Belgium) that accelerates the translation of regenerative medicine from academic research into clinical application. The organization runs five focused Moonshot research programs targeting Cardiovascular regeneration, Type 1 Diabetes cure, Eye (corneal) restoration, Kidney disease (including bioengineered subunits and a wearable artificial kidney now in first-in-human trials), and Osteoarthritis (bio-artificial joints), spanning cell therapy, gene therapy, tissue engineering, organoid technology, biofabrication/3D bioprinting, and biomaterial implants within the ATMP category.

The consortium is anchored by the RegMed XB Pilot Factory, described as one of the largest international regenerative medicine infrastructures, which provides scale-up and de-risking capacity for portfolio projects. It is supported by an ecosystem of more than 60 partners across health foundations (Dutch Heart Foundation, Kidney Foundation, Diabetes Fonds, Oogfonds, ReumaNederland, Dutch Brain Foundation), 11+ academic institutions (LUMC, UMC Utrecht, KU Leuven, TU/e, Maastricht University/MERLN), 30+ industrial partners (including Mimetas for organ-on-chip), and 7 government bodies (Health Holland, RVO, National Growth Fund, and the Ministries of EZK, OCW, and VWS).

RegMed XB does not sell commercial products; instead its revenue mechanics comprise government grants and public funding, seed capital deployment through the FIRST fund (co-managed with Biogeneration Ventures), Valorization Vouchers and business development services, and partner contributions. The value proposition for its stakeholders is the de-risking of promising concepts from academia through proof-of-concept and early clinical stages before commercial partners take them forward, with the organization monetizing principally through program execution, technology transfer, and convening rather than direct product sales.

RegMed XB firmographics

Firmographics
Name
RegMed XB
Legal name
Stichting REGenerative MEDicine crossing Borders
Website
https://regmedxb.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
RegMed XB is a Dutch-Flemish public-private consortium that accelerates regenerative medicine from research to clinic via five Moonshot programs (Cardiovascular, Diabetes, Eye, Kidney, Osteoarthritis), the Pilot Factory infrastructure, and a 60+ partner ecosystem across academia, health foundations, industry, and government.
Ownership category
akta.pro rank

RegMed XB industry classification

Industry
Product category
Regenerative Medicine Research and ATMP Infrastructure
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAGAGAD
Cell Banking & Viral Seed Services (MCB/WCB/VSB)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Regenerative medicine research
  • Tissue engineering infrastructure
  • Cell therapy development
  • ATMP manufacturing services
  • Biofabrication and bioprinting

Where RegMed XB is headquartered

Location

Headquarters

HQ city
Utrecht
HQ country
Netherlands
HQ region
Europe

Offices3 records

Markets served

RegMed XB business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Others

Revenue model

  1. Government Grants and Public Funding: RegMed XB receives support from national and local governments including Health Holland, Ministry of EZK, Ministry of OCW, Ministry of VWS, Netherlands Enterprise Agency (RVO), and National Growth Fund (NGF) to de-risk promising concepts from academia to proof of concept or initial clinical trial stages before commercial partners take over.
  2. Seed Capital and Investment Fund Management: Manages seed capital programs including the FIRST fund (jointly with BGV) for early-stage investment in regenerative and cardiovascular medicine. Receives funding from Thematic Tech Transfer (TTT) program and SRGO subsidy scheme.
  3. Valorization Services: Provides Valorization Vouchers and business development support to help innovators accelerate, de-risk, and scale regenerative therapies. Revenue generated through service fees and successful technology transfer/valorization of research outcomes.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

RegMed XB product offering

Product offering

Core offering

RegMed XB runs multi-year regenerative medicine research programs (five Moonshots covering cardiovascular, Type 1 diabetes, eye, kidney, and osteoarthritis indications) and provides shared Pilot Factory infrastructure that researchers and companies use to scale and de-risk Advanced Therapy Medicinal Products (ATMPs). It supplements these with valorization services (business development, Valorization Vouchers) and the FIRST seed capital fund co-managed with Biogeneration Ventures, functioning as a public-private translation platform rather than a product vendor.

Product overview

RegMed XB is a Dutch-Flemish research consortium (Stichting REGenerative MEDicine crossing Borders and RegMed XB Flanders vzw) operating as a platform organization that accelerates regenerative medicine through five interconnected offerings: (1) Five Moonshot research excellence programs (Cardiovascular, Diabetes, Eye, Kidney, Osteoarthritis) targeting specific chronic diseases through advanced therapy medicinal products; (2) The Pilot Factory, a large-scale infrastructure facility enabling researchers and companies to scale and de-risk regenerative therapies toward market; (3) Valorization services including Valorization Vouchers and business development support; (4) Seed capital through the FIRST fund for early-stage companies; and (5) An annual conference serving as a community platform for the regenerative medicine ecosystem. The organization functions as a public-private partnership connecting academic institutions, health foundations, industrial partners, and governmental agencies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pilot Factory (regenerative medicine infrastructure)
  • Valorization Team Services
  • Seed Capital & FIRST Fund

Quantifiable outcome

  • Growing 100 nephrons per organoid with scalability to 50,000 nephrons in large organoid sheets (Kidney Moonshot)
  • +4 more outcomes

Companies that use RegMed XB

Customer profile

Segments5 records

Ideal customer profiles4 records

RegMed XB technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

RegMed XB partnerships and signals

Strategic signal

Partnerships

18 partnerships are on record, tiered core and major.

  • InsermcoreStrategic or Co-development Partner · 2 July 2025On July 2, 2025, RegMed XB and Inserm (French National Institute of Health and Medical Research) signed a Memorandum of Understanding to strengthen scientific collaboration in biomedical research. The signing was hosted by the French Ambassador to the Netherlands at the French Residence in The Hague.
  • Nakanoshima QrosscoreStrategic or Co-development Partner · 14 October 2024RegMed XB and Nakanoshima Qross (International Hub for Future Medicine based in Osaka, Japan) signed a memorandum of understanding to promote cooperation in regenerative medicine. Nakanoshima Qross delegation visited in October 2025 to strengthen ties.
  • Dutch Heart Foundation (Hartstichting)coreStrategic or Co-development PartnerHealth foundation involved in defining research objectives and providing guidance in research to ensure focus on patients. Co-governs the Cardiovascular Moonshot.
  • Dutch Kidney Foundation (Nierstichting)coreStrategic or Co-development PartnerHealth foundation driving the Kidney Moonshot, defining research objectives and co-governing the program. Supports first-in-human clinical trials for wearable artificial kidney.
  • Diabetes FondscoreStrategic or Co-development PartnerHealth foundation focused on Type 1 diabetes research, co-governing the Diabetes Moonshot and supporting Cure One research center at LUMC.
  • Stichting DONcoreStrategic or Co-development PartnerFoundation with goal to cure Type 1 diabetes, investing nationally and internationally in fundamental and clinical research for a cure.
  • OogfondscoreStrategic or Co-development PartnerHealth foundation focused on preventing eye diseases and supporting people with visual impairments, co-governing the Eye Moonshot.
  • ReumaNederlandcoreStrategic or Co-development PartnerHealth foundation for rheumatism patients (2+ million people), co-governing the Osteoarthritis Moonshot focused on bio-artificial joint development.
  • HersenstichtingcoreStrategic or Co-development PartnerDutch Brain Foundation supporting brain-related research within the RegMed XB ecosystem.
  • Health HollandcoreOthersGovernmental partner providing funding and support for Life Sciences & Health innovation in the Netherlands.
  • Dutch Cardiovascular Alliance (DCVA)coreStrategic or Co-development PartnerStrategic partnership for cardiovascular research collaboration, joint valorization activities, and community events.
  • ATMP XBcoreStrategic or Co-development Partner€3.5 million Interreg-cofunded initiative led by Biovia to reinforce cross-border ecosystem for ATMPs in Flanders and South Netherlands. RegMed XB is a proud contributor.
  • MimetasmajorTechnology or IntegrationIndustrial partner specializing in organ-on-a-chip technology, collaborating with Kidney Moonshot for kidney research and development.
  • KU LeuvencoreStrategic or Co-development PartnerTop-rated academic institution contributing researchers and expertise to multiple Moonshots. Home to Prometheus platform for Skeletal Tissue Engineering.
  • LUMCcoreStrategic or Co-development PartnerLeiden University Medical Center leading Diabetes Moonshot and hosting Cure One research center for Type 1 diabetes cure research.
  • UMC UtrechtcoreStrategic or Co-development PartnerUniversity Medical Center leading Kidney Moonshot (with Prof. Marianne Verhaar) and Cardiovascular Moonshot research activities.
  • TU/e (Eindhoven University of Technology)coreStrategic or Co-development PartnerAcademic partner contributing expertise in biomedical engineering, biomaterials, and biofabrication for Osteoarthritis and Kidney Moonshots.
  • Maastricht University / MUMC+coreStrategic or Co-development PartnerAcademic partner hosting MERLN Institute for Technology-Inspired Regenerative Medicine, contributing to multiple Moonshots including Diabetes and Osteoarthritis.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

RegMed XB competitors and assessment

Company assessment

Emerging players

  • Aspect Biosystems: Canadian biotech developing 3D bioprinted tissue therapeutics with focus on metabolic disease and ophthalmology. Directly comparable on biofabrication and tissue engineering technology overlap with RegMed XB's Osteoarthritis and Eye Moonshots.
  • Mesoblast: Australia-headquartered clinical-stage cell therapy company developing mesenchymal lineage cell therapies for inflammatory and cardiovascular diseases. Overlaps with RegMed XB's Cardiovascular Moonshot in regenerative approaches to heart failure.
  • Vericel Corporation: US commercial-stage cell therapy company marketing MACI (autologous chondrocyte implant for cartilage repair) and Epicel. Directly comparable on cartilage regeneration with overlap to RegMed XB's Osteoarthritis Moonshot.

Broad incumbents

  • Lonza Cell & Gene Technologies: Swiss-headquartered global contract development and manufacturing organization (CDMO) with the largest cell and gene therapy manufacturing footprint. Relevant as the leading ATMP manufacturing partner/infrastructure provider that RegMed XB's Pilot Factory competes with or routes work to.
  • Organogenesis: US-headquartered commercial regenerative medicine company marketing wound care and surgical biologics products. Comparable as a commercial-stage player in regenerative medicine with overlapping musculoskeletal and tissue engineering focus.

Direct peers

  • California Institute for Regenerative Medicine (CIRM): California state-funded agency created by voter proposition that funds stem cell and regenerative medicine research across academic and commercial entities. Operates a comparable model of public funding flowing through a coordinating consortium to advance regenerative therapies.
  • Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW): International stem cell research consortium with nodes in Denmark, the Netherlands, and Australia, funded by the Novo Nordisk Foundation. Directly comparable as a multi-institutional regenerative medicine research consortium with significant long-term foundation backing.
  • Centre for Commercialization of Regenerative Medicine (CCRM): Canadian regenerative medicine consortium that operates a similar public-private model with academic-industry partnerships, pilot manufacturing facilities, and venture creation to commercialize cell and gene therapies. Directly comparable in structure and mission to RegMed XB.
  • Cell and Gene Therapy Catapult: UK-based non-profit consortium accelerating cell and gene therapy commercialization through shared infrastructure, skills development, and clinical trial support. Closely analogous to RegMed XB's consortium-driven ATMP acceleration model across the UK ecosystem.

Regional players

  • Ncardia: Belgium-headquartered stem cell technology company developing iPSC-derived cardiac and neural cell models and manufacturing services. Comparable as a Benelux-based stem cell specialist serving drug discovery and regenerative medicine applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights1 record

Customer concentration

RegMed XB social profiles

Digital presence

RegMed XB compliance and trust

Trust signal

Compliance1 record

RegMed XB financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RegMed XB leadership team

Management profile

Number of profiles

Profiles20 records

RegMed XB funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RegMed XB M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RegMed XB

What does RegMed XB do?

RegMed XB runs multi-year regenerative medicine research programs (five Moonshots covering cardiovascular, Type 1 diabetes, eye, kidney, and osteoarthritis indications) and provides shared Pilot Factory infrastructure that researchers and companies use to scale and de-risk Advanced Therapy Medicinal Products (ATMPs). It supplements these with valorization services (business development, Valorization Vouchers) and the FIRST seed capital fund co-managed with Biogeneration Ventures, functioning as a public-private translation platform rather than a product vendor.

Is RegMed XB a public or private company?

RegMed XB is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was RegMed XB founded?

RegMed XB was founded in 2017. It employs 11 to 50 people.

Where is RegMed XB based?

RegMed XB is headquartered in Utrecht, Netherlands, in the Europe region.

How does RegMed XB make money?

Three revenue lines are on record. Government Grants and Public Funding is the primary driver. The others are seed Capital and Investment Fund Management and valorization Services.

Who are RegMed XB's main competitors?

Emerging players on record are Aspect Biosystems, Mesoblast and Vericel Corporation. Broad incumbents are Lonza Cell & Gene Technologies and Organogenesis. Direct peers are California Institute for Regenerative Medicine (CIRM), Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), Centre for Commercialization of Regenerative Medicine (CCRM) and Cell and Gene Therapy Catapult. Ncardia is listed as a regional player.

Does RegMed XB have an API?

No public API is recorded for RegMed XB.

What industry is RegMed XB in?

RegMed XB's product category is Regenerative Medicine Research and ATMP Infrastructure. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAGAGAD, Cell Banking & Viral Seed Services (MCB/WCB/VSB). Its NAICS code is 541714 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales